Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
about
Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemiaAutologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies
P2860
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Clinicopathological features a ...... the BCL2 inhibitor venetoclax.
@en
Clinicopathological features a ...... the BCL2 inhibitor venetoclax.
@nl
type
label
Clinicopathological features a ...... the BCL2 inhibitor venetoclax.
@en
Clinicopathological features a ...... the BCL2 inhibitor venetoclax.
@nl
prefLabel
Clinicopathological features a ...... the BCL2 inhibitor venetoclax.
@en
Clinicopathological features a ...... the BCL2 inhibitor venetoclax.
@nl
P2093
P50
P1433
P1476
Clinicopathological features a ...... the BCL2 inhibitor venetoclax
@en
P2093
Alexandra Gorelik
David Westerman
John F Seymour
Manu Juneja
Meaghan Wall
Stephen Lade
Surender Juneja
Thomas E Lew
P304
P356
10.1182/BLOOD-2017-01-763003
P407
P577
2017-05-04T00:00:00Z